| Ticker |
CSBR
|
| CIK | 0000771856 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 855 N. WOLFE STREET, SUITE 619, BALTIMORE, MD, 21205 |
| Website | championsoncology.com |
| Phone | 410-369-0365 |
| CEO | Ronnie Morris |
| Employees | 230 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology StrategyAppointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 /Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research ... Champions Oncology Inc (CSBR) Q3 2026 Earnings Call Highlights: Record Services Revenue and ...Despite a slight dip in total revenue, Champions Oncology Inc (CSBR) showcases strong operational performance with record core study revenue and strategic growth investments. Champions Oncology (CSBR) Earnings TranscriptRobert Brainin: Good afternoon, and thank you for joining us for our third quarter fiscal 2026 earnings call. First, we delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA. Second, while quarterly revenue can fluctuate in our business, we remain on track for full year revenue growth and full year positive adjusted EBITDA while continuing to invest in both our data platform and our discovery therapeutics subsidiary. Champions Oncology, Inc. Q3 2026 Earnings Call SummaryMoby summary of Champions Oncology, Inc.'s Q3 2026 earnings call Champions Oncology Reports Revenue of $16.6 MillionCompany remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research ... |
